Capstone Challenge Unlocked: Over $10,000,000 Raised in 70 Days

Capstone Challenge Unlocked: Over $10,000,000 Raised in 70 Days

Dear friends and supporters,

The $10 million Capstone Challenge is complete! Well before our September 10 deadline, over 2,500 supporters contributed over $10,000,000 in gifts ranging from $1 to $1,000,000, which unlocked the $10 million matching grant organized by Tim Ferriss and the Psychedelic Science Funders Collaborative (PSFC). We couldn’t have done it without you.

Thanks to this outpouring of generosity and support from our community, we have successfully completed the $30 million Capstone Campaign which will fund the Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD and other activities required to make MDMA a medicine in the United States, Canada, and Israel.

Read the Press Release

This milestone means we are further on our journey to making MDMA-assisted psychotherapy an approved prescription treatment for PTSD. Phase 3 clinical trials build on the promising results of MAPS’ completed Phase 2 trials and are the final phase of research required by the U.S. Food and Drug Administration (FDA) before deciding whether to approve MDMA as a legal prescription treatment for PTSD. Enrollment for our second Phase 3 clinical trial has now started.

These pledges and donations were made over the course of the Capstone Campaign. Our gratitude goes to the 3,400+ supporters who contributed to make this work possible. We share this list in part to show that a community has gathered to make a difference. In addition to the names below, 1,447 anonymous donors raised a collective $4,953,087.

We extend a special thanks to the following donors who made this challenge grant possible and to those who helped get this campaign started:

If you did not have a chance to donate to the Capstone Challenge, you can make a donation to MAPS at any time to help us continue advancing the field of psychedelic science and create new treatments for mental health conditions. 

Thank you for your support! We could not have achieved this milestone without you.

With gratitude,

Rick Doblin, Ph.D.